Nkarta, Inc.
Nkarta is a biotechnology company dedicated to harnessing the power of natural killer (NK) cells for the treatment of autoimmune diseases and cancer. The company's mission is to discover, develop, and deliver off-the-shelf NK cell therapies that profoundly impact patients' response, quality of life, and overall survival. Founded in 2015, Nkarta combines proprietary NK cell expansion technology with cell engineering to generate potent, durable, and accessible cell therapies. The company is committed to innovation, diversity, and making advanced treatments broadly available.
Industries
Nr. of Employees
medium (51-250)
Nkarta, Inc.
Products
Investigational CAR NK cell therapy targeting CD19
An allogeneic, donor-derived CAR NK cell candidate designed to target CD19-expressing B cells for the treatment of B cell-mediated autoimmune diseases; intended for off-the-shelf outpatient administration.
Investigational CAR NK cell therapy targeting CD19
An allogeneic, donor-derived CAR NK cell candidate designed to target CD19-expressing B cells for the treatment of B cell-mediated autoimmune diseases; intended for off-the-shelf outpatient administration.
Services
GMP manufacturing and process transfer (internal)
Internal development and execution of GMP manufacturing processes for allogeneic cell therapy candidates and transfer of processes to GMP operations.
Analytical method development and QC support (internal)
Development, qualification and transfer of cell-based and molecular assays to support process development, release testing and regulatory filings.
Preclinical pharmacology and in vivo model development (internal)
Design and execution of in vivo efficacy and pharmacology studies using oncology and immunology models to support lead selection and IND-enabling data generation.
Bioinformatics and -omics data analysis (internal)
In-house computational analysis, pipeline development and integration of public and proprietary -omics datasets to support target discovery and biomarker strategies.
GMP manufacturing and process transfer (internal)
Internal development and execution of GMP manufacturing processes for allogeneic cell therapy candidates and transfer of processes to GMP operations.
Analytical method development and QC support (internal)
Development, qualification and transfer of cell-based and molecular assays to support process development, release testing and regulatory filings.
Preclinical pharmacology and in vivo model development (internal)
Design and execution of in vivo efficacy and pharmacology studies using oncology and immunology models to support lead selection and IND-enabling data generation.
Bioinformatics and -omics data analysis (internal)
In-house computational analysis, pipeline development and integration of public and proprietary -omics datasets to support target discovery and biomarker strategies.
Expertise Areas
- Cell therapy process development
- Allogeneic NK cell engineering
- Analytical assay development for cell therapies
- Preclinical in vivo pharmacology and model development
Key Technologies
- Flow cytometry (multicolor)
- qPCR
- ELISA / MSD immunoassays
- Cell-based cytotoxicity and proliferation assays